Focus Areas

Our research efforts are focused on basic and translational science in areas where we think we can be the most helpful: Oncology, Immunology, Neuroscience, Metabolism, and Infectious Disease. See More

Pipeline

We focus our research and development practice on discovering and developing potential new medicines for unmet medical needs. Right now, our pipeline has over 25 new molecular entities in clinical development. View Our Pipeline

RECENT ACCOMPLISHMENTS

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011

Here we show that the pro-survival protein MCL1 (ref. 3) is a crucial regulator of apoptosis triggered by antitubulin chemotherapeutics. View Abstract on PubMed

Zelboraf Approved.

Zelboraf is an oral, small molecule, kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

Read the Press Release
View All